Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);
HER2-positive Gastric Cancer
DRUG: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
ORR (Objective control rate), The rate of CR and PR, determined using RECIST v1.1 criteria, up to 12 months
DCR (Disease control rate), The rate of CR, PR plus SD, up to 12 months|PFS (Progression-Free survival), From the date Into this study (signed ICF) to tumor progression or death for any, up to 12 months|OS(Overall survival), Baseline until death from any cause, up to approximately 24 months
According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);